Systemic treatment for hepatocellular carcinoma (HCC) has been boosted by the
incorporation of new agents after many negative phase III trials in the decade since the …

The liver plays a central role in the pharmacokinetics of the majority of drugs. Liver
dysfunction may not only reduce the blood/plasma clearance of drugs eliminated by hepatic …

Objectives: To develop evidence-based recommendations for clinicians caring for adults
with acute or acute on chronic liver failure in the ICU. Design: The guideline panel …

Drug induced liver injury (DILI) is a common cause of acute liver injury. Paracetamol, also
known as acetaminophen, is a widely used anti-pyretic that has long been established to …

Pain management in patients with cirrhosis is a difficult clinical challenge for health care
professionals, and few prospective studies have offered an evidence-based approach. In …

Despite regular use of drugs for critically ill patients, overall data are limited regarding the
impact of critical illness on pharmacokinetics (PK). Designing safe and effective drug …

Background Most drugs have not been well studied in cirrhosis; recommendations on safe
use are based largely on experience and/or expert opinion, with dosing recommendations …

Acute, symptomatic seizures or epilepsy may complicate the course of hepatic disease.
Choosing the most appropriate antiepileptic drug in this setting represents a difficult …

Drug-induced liver injury is a significant and still unresolved clinical problem. Limitations to
knowledge about the mechanisms of toxicity render incomplete the detection of hepatotoxic …

While the pace of discovery of new agents, mechanisms and risk factors involved in drug-
induced liver injury (DILI) remains brisk, advances in the treatment of acute DILI seems slow …